More than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgery

Data demonstrated statistically significant and clinically meaningful survival benefit and manageable safety profile

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.